Tuesday, 29 October 2013

Bristol-Myers Squibb announced promising results from an expanded phase 1 dose-ranging study of its lung cancer drug nivolumab « New Drug Approvals

Bristol-Myers Squibb announced promising results from an expanded phase 1 dose-ranging study of its lung cancer drug nivolumab « New Drug Approvals:

'via Blog this'
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)